BioRestorative Therapies (BRTX) Scheduled to Post Quarterly Earnings on Tuesday

BioRestorative Therapies (NASDAQ:BRTX) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.57) EPS for the quarter. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 9,873.97% and a negative return on equity of 114.84%. On average, analysts expect BioRestorative Therapies to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioRestorative Therapies Trading Down 4.7 %

Shares of NASDAQ BRTX opened at $1.41 on Tuesday. BioRestorative Therapies has a 12-month low of $1.20 and a 12-month high of $7.13. The stock has a 50 day simple moving average of $1.35 and a 200-day simple moving average of $1.61.

Insiders Place Their Bets

In other BioRestorative Therapies news, major shareholder Dale Broadrick purchased 36,374 shares of the stock in a transaction dated Wednesday, February 7th. The shares were bought at an average cost of $1.38 per share, with a total value of $50,196.12. Following the completion of the acquisition, the insider now owns 363,419 shares of the company’s stock, valued at $501,518.22. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders acquired 124,123 shares of company stock worth $165,752. 21.60% of the stock is owned by company insiders.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.